The breadth and depth of data across multiple leukemia subtypes and settings strengthen revumenib's competitive position as a first-in-class menin inhibitor. Traders should watch for updates on the ongoing pivotal frontline combination trials, which could drive further upside if results confirm these early signals.
Price Chart
Executive Summary
Syndax presented 12 abstracts on revumenib at EHA 2026, including real-world data showing 82% ORR in R/R NPM1m/KMT2Ar patients, a Phase 1 frontline combo trial with 97% CRc, and the SAVE trial with 88% ORR. The data reinforce revumenib's broad activity across multiple acute leukemia subtypes and settings, supporting its commercial potential and ongoing pivotal trials.
Key Facts
- Real-world ROAR study: 82% ORR (9/11) and 64% CR/CRh (7/11) in R/R NPM1m or KMT2Ar acute leukemia.
- Phase 1 frontline combo: 97% CRc (34/35) and 86% MRD negativity (25/29) in newly diagnosed NPM1m/KMT2Ar AML.
- SAVE trial (R/R): 88% ORR (37/42), 68% MRD negativity (25/37) among responders, 45% transplant rate (19/42).
- Post-hoc AUGMENT-101: 95% estimated 12-month OS in patients resuming revumenib post-HSCT.
- NUP98r data: 28% ORR (7/25) in heavily pretreated patients with poor-prognosis subtype.
- Safety consistent with established profile; no new safety signals across studies.
Financial Impact
No financial figures provided; data supports revumenib's potential label expansion and market penetration in acute leukemia, a multi-billion-dollar market.
Risk Factors
- Competition from other menin inhibitors in development (e.g., Kura Oncology's ziftomenib).
- Regulatory risks for label expansion; pivotal trial results may differ from early-phase data.
- Commercial execution risk; revumenib is recently approved and market adoption is still ramping.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3310342 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 14, 2026 11w ago | 8-K | $24.13 $20.29 | ▼ −15.91% | ▼ −18.41% | $17.60 (−27.06%) |
Jul 1, 2026 13w ago | Press Release | $21.82 $19.48 | ▼ −10.72% | ▼ −10.31% | $17.60 (−19.34%) |
Jun 11, 2026 16w ago | Press Release | $17.91 $24.84 | ▲ +38.69% | ▲ +36.80% | $17.60 (−1.73%) |
Jun 10, 2026 16w ago | 8-K | $17.91 $24.84 | ▲ +38.69% | ▲ +36.80% | $17.60 (−1.73%) |
Jun 4, 2026 17w ago | Press Release | $17.34 $22.08 | ▲ +27.34% | ▲ +25.47% | $17.60 (+1.50%) |
Jun 4, 2026 17w ago | DEFA14A | $18.02 $21.82 | ▲ +21.09% | ▲ +22.46% | $17.60 (−2.33%) |
Jun 4, 2026 17w ago | 8-K | $18.02 $21.82 | ▲ +21.09% | ▲ +22.46% | $17.60 (−2.33%) |
Apr 30, 2026 22w ago | DEFA14A | $19.11 $18.85 | ▼ −1.36% | ▼ −6.64% | $17.60 (−7.90%) |
Apr 24, 2026 23w ago | Press Release | $21.39 $19.77 | ▼ −7.57% | ▼ −11.60% | $17.60 (−17.72%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access